Prevention of Iron Deficiency Anemia Post-delivery
Status:
Not yet recruiting
Trial end date:
2025-12-01
Target enrollment:
Participant gender:
Summary
PRIORITY is designed as a 2-arm, randomized-controlled trial focused on postpartum women. The
trial will recruit women who are diagnosed with moderate anemia based on a blood sample taken
6-48 hours after childbirth. A total of 4,800 eligible women, or 600 women per research site,
will be consented and enrolled in the trial. The study hypothesizes that at 6 weeks
post-delivery, prevalence of the non-anemic state in women in that received a single-dose IV
iron infusion between 6 and 48 hours after delivery and prior to discharge from the facility
will be greater than that of women given a supply of oral iron tablets taken twice daily for
6 weeks.
Phase:
Phase 3
Details
Lead Sponsor:
NICHD Global Network for Women's and Children's Health
Collaborators:
Aga Khan University Bill and Melinda Gates Foundation Boston University Columbia University Indiana University Institute of Nutrition of Central America and Panama International Centre for Diarrhoeal Disease Research, Bangladesh Kinshasa School of Public Health KLE University Jawaharlal Nehru Medical College Lata Medical Research Foundation, Nagpur Moi University RTI International Thomas Jefferson University University of Alabama at Birmingham University of Colorado, Denver University of North Carolina University of Virginia University Teaching Hospital, Lusaka, Zambia